Related Experiment Videos
"Holidays" for osteoporosis drugs: A case-based approach
Panagiotis Anagnostis1,2,3, Stavroula A Paschou4, Eustathios Kenanidis2,3
1Unit of Reproductive Endocrinology, First Department of Obstetrics and Gynaecology, Medical School, Aristotle University of Thessaloniki, Greece.
Case Reports in Women'S Health
|August 22, 2019
Summary
Consider a drug holiday for patients with low fracture risk after 5 years of alendronate or 3 years of zoledronic acid/risedronate. This strategy is not suitable for denosumab, estrogen, SERMs, or teriparatide.
Area of Science:
- Osteoporosis management
- Pharmacology
- Bone health
Background:
- Bisphosphonates like alendronate, zoledronic acid, and risedronate are common treatments for osteoporosis.
- Prolonged use of these medications raises questions about long-term efficacy and potential side effects.
- Determining optimal treatment duration is crucial for patient care and fracture prevention.